Lysosomal degradation of membrane lipids

FEBS Letters

Volumn 584, Issue 9, 2010, Pages 1700-1712

  Kolter, Thomas ^a   Sandhoff, Konrad ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Endosome; GM2 activator; Lysosome; Niemann Pick disease, type C2 protein; Saposin; Sphingolipid activator protein

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CERAMIDE; CHOLESTEROL; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; LIPID BINDING PROTEIN; MEMBRANE LIPID; NIEMANN PICK DISEASE PROTEIN C2; PHOSPHORUS DERIVATIVE; PROSAPOSIN; SPHINGOLIPID; SPHINGOLIPID ACTIVATOR PROTEIN; SPHINGOLIPID ACTIVATOR PROTEIN A; SPHINGOLIPID ACTIVATOR PROTEIN B; SPHINGOLIPID ACTIVATOR PROTEIN C; SPHINGOLIPID ACTIVATOR PROTEIN D; SPHINGOMYELIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; NPC2 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; AUTOPHAGY; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL METABOLISM; ENDOCYTOSIS; ENDOSOME; ENZYME DEFECT; GENETIC DISORDER; HUMAN; HYDROLYSIS; LIPID COMPOSITION; LIPID DEGRADATION; LIPID MEMBRANE; LYSOSOME; LYSOSOME MEMBRANE; LYSOSOME STORAGE DISEASE; MEMBRANE STABILIZATION; NIEMANN PICK DISEASE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIGEN PRESENTATION; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; ENDOCYTOSIS; G(M2) ACTIVATOR PROTEIN; GLYCOPROTEINS; HUMANS; LIPID METABOLISM; LYSOSOMES; MEMBRANE LIPIDS; MODELS, BIOLOGICAL; SAPOSINS; SIGNAL TRANSDUCTION;

EID: 77951924919     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.10.021     Document Type: Review

References (216)

1. Luzio J.P., Pryor P.R., Bright N.A. Lysosomes: fusion and function. Nat. Rev. Mol. Cell. Biol. 2007, 8:622-632.
2. Sagné C., Gasnier B. Molecular physiology and pathophysiology of lysosomal membrane transporters. J. Inherit. Metab. Dis. 2008, 31:258-266.
3. Ruivo R., Anne C., Sagné C., Gasnier B. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim. Biophys. Acta 2009, 1793:636-649.
4. Augustin R., Riley J., Moley K.H. GLUT8 contains a [DE]XXXL[LI] sorting motif and localizes to a late endosomal/lysosomal compartment. Traffic 2005, 6:1196-1212.
5. Schmidt S., Joost H.G., Schürmann A. GLUT8, the enigmatic intracellular hexose transporter. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E614-E618.
6. Rutsch F., Gailus S., Miousse I.R., Suormala T., Sagné C., Toliat M.R., Nürnberg G., Wittkampf T., Buers I., Sharifi A., Stucki M., Becker C., Baumgartner M., Robenek H., Marquardt T., Höhne W., Gasnier B., Rosenblatt D.S., Fowler B., Nürnberg P. Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B12 metabolism. Nat. Genet. 2009, 41:234-239.
7. Kurz T., Terman A., Gustafsson B., Brunk U.T. Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 2008, 129:389-406.
8. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
9. Pyne N.J., Long J.S., Lee S.C., Loveridge C., Gillies L., Pyne S. New aspects of sphingosine 1-phosphate signaling in mammalian cells. Adv. Enzyme Regulat. 2009, 49:214-221.
10. Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 2009, 10:623-635.
11. Callahan J.W., Bagshaw R.D., Mahuran D.J. The integral membrane of lysosomes: its proteins and their roles in disease. J. Proteomics 2009, 72:23-33.
12. Lübke T., Lobel P., Sleat D.E. Proteomics of the lysosome. Biochim. Biophys. Acta 2009, 1793:625-635.
13. Mellman I., Fuchs R., Helenius A. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 1986, 55:663-700.
14. Hinton A., Bond S., Forgac M. V-ATPase functions in normal and disease processes. Pflügers Arch. 2009, 457:589-598.
15. Pryor P.R., Luzio J.P. Delivery of endocytosed membrane proteins to the lysosome. Biochim. Biophys. Acta 2009, 1793:615-624.
16. Reczek D., Schwake M., Schröder J., Hughes H., Blanz J., Jin X., Brondyk W., Van Patten S., Edmunds T., Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783.
17. Luzio J.P., Bright N.A., Pryor P.R. The role of calcium and other ions in sorting and delivery in the late endocytic pathway. Biochem. Soc. Trans. 2007, 35:1088-1091.
18. Hurwitz R., Ferlinz K., Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol. Chem. Hoppe-Seyler 1994, 375:447-450.
19. Kölzer M., Werth N., Sandhoff K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 2004, 559:96-98.
20. Schmid S., Fuchs R., Kielian M., Helenius A., Mellman I. Acidification of endosome subpopulations in wild-type Chinese hamster ovary cells and temperature-sensitive acidification-defective mutants. J Cell Biol. 1989, 108:1291-1300.
21. Grabe M., Oster G. Regulation of organelle acidity. J. Gen. Physiol. 2001, 117:329-344.
22. Li S.C., Kane P.M. The yeast lysosome-like vacuole: Endpoint and crossroads. Biochim. Biophys. Acta 2009, 1793:650-663.
23. Rybak S.L., Lanni F., Murphy R.F. Theoretical Considerations on the Role of Membrane Potential in the Regulation of Endosomal pH. Biophys. J. 1997, 73:674-687.
24. Crichton R. Iron Metabolism - From Molecular Mechanisms to Clinical Consequences 2009, John Wiley & Sons, Chichester, UK. third ed.
25. Massaro E.J. Handbook of Copper Pharmacology and Toxicology 2002, Humana Press, Totowa, NJ.
26. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
27. Kurz T., Terman A., Gustafsson B., Brunk U.T. Lysosomes and oxidative stress in aging and apoptosis. Biochim. Biophys. Acta 2008, 1780:1291-1303.
28. Tint G.S., Pentchev P., Xu G., Batta A.K., Shefer S., Salen G., Honda A. Cholesterol and oxygenated cholesterol concentrations are markedly elevated in peripheral tissue but not in brain from mice with the Niemann-Pick type C phenotype. J. Inherit. Metab. Dis. 1998, 21:853-863.
29. Zhang J.R., Coleman T., Langmade S.J., Scherrer D.E., Lane L., Lanier M.H., Feng C., Sands M.S., Schaffer J.E., Semenkovich C.F., Ory D.S. Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J. Clin. Invest. 2008, 118:2281-2290.
30. Ballabio A., Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 2009, 1793:684-696.
31. Staretz-Chacham O., Lang T.C., LaMarca M.E., Krasnewich D., Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics 2009, 123:1191-1207.
32. Walkley S.U. Pathogenic cascades in lysosomal disease-why so complex?. J. Inherit. Metab. Dis. 2009, 32:181-189.
33. Platt F.M., Lachmann R.H. Treating lysosomal storage disorders: current practice and future prospects. Biochim. Biophys. Acta 2009, 1793:737-745.
34. Kolter T., Sandhoff K. Sphingolipid metabolism diseases. Biochim. Biophys. Acta 2006, 1758:2057-2079.
35. Sabourdy F., Kedjouar B., Sorli C., Colié S., Milhas D., Salma Y., Levade T. Functions of sphingolipid metabolism in mammals - lessons from genetic defects. Biochim. Biophys. Acta 2008, 1781:145-183.
36. Rao R.P., Acharya J.K. Sphingolipids and membrane biology as determined from genetic models. Prostagland. Lipid Mediat. 2008, 85:1-16.
37. Walkley S.U., Vanier M.T. Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta 2009, 1793:726-736.
38. Aridor M., Hannan L.A. Traffic jam: a compendium of human diseases that affect intracellular transport processes. Traffic 2000, 1:836-851.
39. Aridor M., Hannan L.A. Traffic jams II: an update of diseases of intracellular transport. Traffic 2002, 3:781-790.
40. Liscum L. Niemann-Pick type C mutations cause lipid traffic jam. Traffic 2000, 1:218-225.
41. Lloyd-Evans E., Morgan A.J., He X., Smith D.A., Elliot-Smith E., Sillence D.J., Churchill G.C., Schuchman E.H., Galione A., Platt F.M. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 2008, 14:1247-1255.
42. Smith D., Wallom K.L., Williams I.M., Jeyakumar M., Platt F.M. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol. Dis. 2009, 34:406-416.
43. Settembre C., Fraldi A., Jahreiss L., Spampanato C., Venturi C., Medina D., de Pablo R., Tacchetti C., Rubinsztein D.C., Ballabio A. A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet. 2008, 17:119-129.
44. Settembre C., Fraldi A., Rubinsztein D.C., Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy 2008, 4:113-114.
45. Dierks T., Lars Schlotawa L., Frese M.-A., Radhakrishnan K., von Figura K., Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim. Biophys. Acta 2009, 1793:710-725.
46. Nixon R.A., Yang D.-S., Lee J.-H. Neurodegenerative lysosomal disorders - a continuum from development to late age. Autophagy 2008, 4:590-599.
47. Jin L.W., Shie F.S., Maezawa I., Vincent I., Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 2004, 164:975-985.
48. Schulze H., Kolter T., Sandhoff K. Principles of lysosomal membrane degradation: cellular topology and biochemistry of lysosomal lipid degradation. Biochim. Biophys. Acta 2009, 1793:674-683.
49. Tettamanti G., Bassi R., Viani P., Riboni L. Salvage pathways in glycosphingolipid metabolism. Biochimie 2003, 85:432-437.
50. Boya P., Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
51. Okino N., He X., Gatt S., Sandhoff K., Ito M., Schuchman E.H. The reverse activity of human acid ceramidase. J. Biol. Chem. 2003, 278:29948-29953.
52. Hiraoka M., Abe A., Shayman J.A. Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J. Biol. Chem. 2002, 277:10090-10099.
53. Abe A., Hiraoka M., Shayman J.A. The acylation of lipophilic alcohols by lysosomal phospholipase A2. J. Lipid Res. 2007, 48:2255-2263.
54. Kirkegaard T., Jäättelä M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 2009, 1793:746-754.
55. Kolter T., Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 2005, 21:81-103.
56. Braulke T., Bonifacino J.S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 2009, 1793:605-614.
57. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78:857-902.
58. Gould G.W., Lipincott-Schwartz J. New roles for endosomes: from vesicular carriers to multi-purpose platforms. Nat. Rev. Mol. Cell Biol. 2009, 10:287-292.
59. van Meel E., Klumperman J. Imaging and imagination: understanding the endo-lysosomal system. Histochem. Cell Biol. 2008, 129:253-266.
60. Davies B.A., Lee J.R.E., Oestreich A.J., Katzmann D.J. Membrane protein targeting to the MVB/lysosome. Chem. Rev. 2009, 109:1575-1586.
61. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
62. Eskelinen E.L., Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 2009, 1793:664-673.
63. Jaeger P.A., Wyss-Coray T. All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol. Neurodegener. 2009, 4:16.
64. Nakamura N., Matsuura A., Wada Y., Ohsumi Y. Acidification of vacuoles is required for autophagic degradation in the yeast, Saccharomyces cerevisiae. J. Biochem. 1997, 121:338-344.
65. Amidon B., Brown A., Waite M. Transacylase and phospholipases in the synthesis of bis(monoacylglycero)phosphate. Biochemistry 1996, 35:13995-14002.
66. Brotherus J., Renkonen O., Herrmann J., Fischer W., Herrmann J. Novel stereoconfiguration in lyso-bis-phosphatidic acid of cultured BHK-cells. Chem. Phys. Lipids 1974, 13:178-182.
67. Heravi J., Waite M. Transacylase formation of bis(monoacylglycerol)phosphate. Biochim. Biophys. Acta 1999, 1437:277-286.
68. Hullin-Matsuda F., Kawasaki K., Delton-Vandenbroucke I., Xu Y., Nishijima M., Lagarde M., Schlame M., Kobayashi T. De novo biosynthesis of the late endosome lipid, bis(monoacylglycero)phosphate. J. Lipid Res. 2007, 48:1997-2008.
69. Sorice M., Circella A., Cristea I.M., Garofalo T., Di Renzo L., Alessandri C., Valesini G., Esposti M.D. Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ. 2004, 11:1133-1145.
70. Kolter T., Sandhoff K. Sphingolipids - their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew. Chem. Int. Ed. 1999, 38:1532-1568.
71. Kolter T., Proia R.L., Sandhoff K. Minireview: combinatorial ganglioside biosynthesis. J. Biol. Chem. 2002, 277:25859-25862.
72. Sandhoff K., Kolter T., Harzer K. Sphingolipid activator proteins. The Metabolic and Molecular Bases of Inherited Disease 2001, vol. III:3371-3388. McGraw-Hill, New York, (Chapter 134). 8th ed.
73. Linke T., Wilkening G., Lansmann S., Moczall H., Bartelsen O., Weisgerber J., Sandhoff K. Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol. Chem. 2001, 382:83-90.
74. Burke J.E., Dennis E.A. Phospholipase A2 biochemistry. Cardiovasc. Drugs Ther. 2009, 23:49-59.
75. Goni F.M., Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 2002, 531:38-46.
76. van Weely S., Brandsma M., Strijland A., Tager J.M., Aerts J.M. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1993, 1181:55-62.
77. Yildiz Y., Matern H., Thompson B., Allegood J.C., Warren R.L., Ramirez D.M., Hammer R.E., Hamra F.K., Matern S., Russell D.W. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 2006, 116:2985-2994.
78. Hayashi Y., Okino N., Kakuta Y., Shikanai T., Tani M., Narimatsu H., Ito M. Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase. J Biol Chem. 2007, 282:30889-30900.
79. Fürst W., Sandhoff K. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta 1992, 1126:1-16.
80. Suzuki K., Chen G.C. GM1-gangliosidosis (generalized gangliosidosis). Morphology and chemical pathology. Pathol. Eur. 1968, 3:389-408.
81. Harzer K., Paton B.C., Poulos A., Kustermann-Kuhn B., Roggendorf W., Grisar T., Popp M. Sphingolipid activator protein (SAP) deficiency in a 16-week old atypical Gaucher disease patient and his fetal sibling; biochemical signs of combined sphingolipidosis. Eur. J. Pediatr. 1989, 149:31-39.
82. Sandhoff K., Kolter T. Topology of glycosphingolipid degradation. Trends Cell Biol. 1996, 6:98-103.
83. Eskelinen E.-L., Tanaka Y., Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003, 13:137-145.
84. Henning R., Stoffel W. Glycosphingolipids in lysosomal membranes. Hoppe-Seyler's Z. Physiol. Chem. 1973, 354:760-770.
85. Tettamanti G. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconjugate J. 2004, 20:301-317.
86. Saksena S., Ji S., Chu T., Emr S.D. ESCRTing proteins in the endocytic pathway. Trends Biochem. Sci 2007, 23:519-547.
87. Piper R.C., Katzmann D.J. Biogenesis and function of multivesicular bodies. Annu. Rev. Cell. Dev. Biol. 2007, 23:519-547.
88. Hopkins C.R., Gibson A., Shipman M., Miller K. Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum. Nature 1990, 346:335-339.
89. Katzmann D.J., Babst M., Emr S.D. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 2001, 106:145-155.
90. Umebayashi K. The roles of ubiquitin and lipids in protein sorting along the endocytic pathway. Cell. Struct. Funct. 2003, 28:443-453.
91. van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: where they are and how they behave. Nature Rev. Mol. Cell. Biol. 2008, 9:112-124.
92. Kobayashi T., Beuchat M.H., Chevallier J., Makino A., Mayran N., Escola J.-M., Lebrand C., Cosson P., Kobayashi T., Gruenberg J. Separation and characterization of late endosomal membrane domains. J. Biol. Chem. 2002, 277:32157-32164.
93. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443:651-657.
94. Matsuzawa Y., Hostetler K.Y. Degradation of bis(monoacylglycero)phosphate by an acid phosphodiesterase in rat liver lysosomes. J. Biol. Chem. 1979, 254:5997-6001.
95. Kobayashi T., Stang E., Fang K.S., de Moerloose P., Parton R.G., Gruenberg J. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature 1998, 392:193-197.
96. Chojnacki T., Dallner G. The biological role of dolichol. Biochem. J. 1988, 251:1-9.
97. Matsuo H., Chevallier J., Mayran N., Le Blanc I., Ferguson C., Faure J., Blanc N.S., Matile S., Dubochet J., Sadoul R., Parton R.G., Vilbois F., Gruenberg J. Role of LBPA and Alix in multivesicular liposome formation and endosome organization. Science 2004, 303:531-534.
98. Odorizzi G. The multiple personalities of Alix. J. Cell Sci. 2006, 119:3025-3032.
99. Falguières T., Luyet P.-P., Gruenberg J. Molecular assemblies and membrane domains in multivesicular endosome dynamics. Exp. Cell Res. 2009, 315:1567-1573.
100. Abrami L., Lindsay M., Parton R.G., Leppla S.H., van der Goot F.G. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 2004, 166:645-651.
101. Le Blanc I., Luyet P.-P., Pons V., Ferguson C., Emans N., Petiot A., Mayran N., Demaurex N., Fauré J., Sadoul R., Parton R.G., Gruenberg J. Endosome-to-cytosol transport of viral nucleocapsids. Nat. Cell Biol. 2005, 7:653-664.
102. Chevallier J., Chamoun Z., Jiang G., Prestwich G., Sakai N., Matile S., Parton R.G., Gruenberg J. Lysobisphosphatidic acid controls endosomal cholesterol levels. J. Biol. Chem. 2008, 283:27871-27880.
103. Frederick T.E., Chebukati J.N., Mair C.E., Goff P.C., Fanucci G.E. Bis(monoacylglycero)phosphate forms stable small lamellar vesicle structures: insights into vesicular body formation in endosomes. Biophys. J. 2009, 96:1847-1855.
104. Locatelli-Hoops S., Remmel N., Klingenstein R., Breiden B., Rossocha M., Schoeniger M., Koenigs C., Saenger W., Sandhoff K. Saposin A mobilizes lipids from low cholesterol and high bis(monoacylglycerol)phosphate-containing membranes: patient variant Saposin A lacks lipid extraction capacity. J. Biol. Chem. 2006, 281:32451-32460.
105. Remmel N., Locatelli-Hoops S., Breiden B., Schwarzmann G., Sandhoff K. Saposin B mobilizes lipids from cholesterol-poor and bis(monoacylglycero)phosphate-rich membranes at acidic pH. Unglycosylated patient variant saposin B lacks lipid-extraction capacity. FEBS J. 2007, 274:3405-3420.
106. Werth N., Schuette C.G., Wilkening G., Lemm T., Sandhoff K. Degradation of membrane-bound ganglioside GM2 by β-hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. J. Biol. Chem. 2001, 276:12685-12690.
107. Wilkening G., Linke T., Uhlhorn-Dierks G., Sandhoff K. Degradation of membrane-bound Ganglioside GM1. J. Biol. Chem. 2000, 275:35814-35819.
108. Hepbildikler S.T., Sandhoff R., Kölzer M., Proia R.L., Sandhoff K. Physiological substrates for human lysosomal β-hexosaminidase S. J. Biol. Chem. 2002, 277:2562-2572.
109. Linke T., Wilkening G., Sadeghlar F., Mozcall H., Bernardo K., Schuchman E., Sandhoff K. Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J. Biol. Chem. 2001, 276:5760-5768.
110. Berent S.L., Radin N.S. Mechanism of activation of glucocerebrosidase by co-β-glucosidase (glucosidase activator protein). Biochim. Biophys. Acta 1981, 664:572-582.
111. Sarmientos F., Schwarzmann G., Sandhoff K. Specificity of human glucosylceramide β-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system. Eur. J. Biochem. 1986, 160:527-535.
112. Salvioli R., Tatti M., Ciaffoni F., Vaccaro A.M. Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids. FEBS Lett. 2000, 472:17-21.
113. Elojeimy S., Holman D.H., Liu X., El-Zawahry A., Villani M., Cheng J.C., Mahdy A., Zeidan Y., Bielwaska A., Hannun Y.A., Norris J.S. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006, 580:4751-4756.
114. Abe A., Shayman J.A. The role of negatively charged lipids in lysosomal phospholipase A2 function. J. Lipid Res. 2009, 50:2027-2035.
115. Friedland N., Liou H.L., Lobel P., Stock A.M. Structure of a cholesterol-binding protein deficient in Niemann-Pick type C2 disease. Proc. Natl. Acad. Sci. USA 2003, 100:2512-2517.
116. Möbius W., van Donselaar E., Ohno-Iwashita Y., Shimada Y., Heijnen H.F., Slot J.W., Geuze H.J. Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway. Traffic 2003, 4:222-231.
117. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 2006, 86:1237-1261.
118. Schoer J.K., Gallegos A.M., McIntosh A.L., Starodub O., Kier A.B., Billheimer J.T., Schroeder F. Lysosomal membrane cholesterol dynamics. Biochemistry 2000, 39:7662-7677.
119. Gallegos A.M., Atshaves B.P., Storey S.M., Starodub O., Petrescu A.D., Huang H., McIntosh A.L., Martin G.G., Chao H., Kier A.B., Schroeder F. Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. Progr. Lipid Res. 2001, 40:498-563.
120. Möbius W., Herzog V., Sandhoff K., Schwarzmann G. Intracellular distribution of a biotin-labeled ganglioside GM1 by immunoelectron microscopy after endocytosis in fibroblasts. J. Histochem. Cytochem. 1999, 47:1005-1014.
121. Möbius W., Herzog V., Sandhoff K., Schwarzmann G. Gangliosides are transported from the plasma membrane to intralysosomal membranes as revealed by immuno-electron microscopy. Biosci. Rep. 1999, 19:307-316.
122. London M., London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J. Biol. Chem. 2004, 279:9997-10004.
123. Castro B.M., Silva L.C., Fedorov A., de Almeida R.F., Prieto M. Cholesterol-rich fluid membranes solubilize ceramide domains. Implications for the structure and dynamics of mammalian intracellular and plasma membrane. J. Biol. Chem. 2009, 284:22978-22987.
124. Massey J.B. Interaction of ceramides with phosphatidylcholine, sphingomyelin and sphingomyelin/cholesterol bilayers. Biochim. Biophys. Acta 2001, 1510:167-184.
125. Xu X., Bittman R., Duportail G., Heissler D., Vilcheze C., London E. Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebrosides, and ceramide. J. Biol. Chem. 2001, 276:33540-33546.
126. Lange Y., Ye J., Steck T.L. Activation of membrane cholesterol by displacement from phospholipids. J. Biol. Chem. 2005, 280:36126-36131.
127. Osiecki-Newman K., Legler G., Grace M., Dinur T., Gatt S., Desnick R.J., Grabowski G.A. Human acid β-glucosidase: Inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites. Enzyme 1988, 40:173-188.
128. Bernardo K., Hurwitz R., Zenk T., Desnick R.J., Ferlinz K., Schuchman E.H., Sandhoff K. Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem. 1995, 70:11098-11102.
129. Neumann S., van Meer Sphingolipid management by an orchestra of lipid transfer proteins. Biol. Chem. 2008, 389:1349-1360.
130. Malinina L., Malakhova M.L., Teplov A., Brown R.E., Patel D.J. Structural basis for glycosphingolipid transfer specificity. Nature 2004, 430:1048-1053.
131. Munford R.S., Sheppard P.O., O'Hara P.J. Saposin-like proteins (SAPLIP) carry out diverse functions on a common backbone structure. J. Lipid. Res. 1995, 36:1653-1663.
132. Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M., Nishijima M. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003, 426:803-809.
133. Coe N.R., Bernlohr D.A. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta 1998, 1391:287-306.
134. Mattjus P. Glycolipid transfer proteins, membrane interaction. Biochim. Biophys. Acta 2009, 1788:267-272.
135. Snook C.F., Jones J.A., Hannun Y.A. Sphingolipid-binding proteins. Biochim. Biophys. Acta 2008, 1761:927-946.
136. Boes M., Stoppelenburg A.J., Sillé F.C. Endosomal processing for antigen presentation mediated by CD1 and Class I major histocompatibility complex: roads to display or destruction. Immunology 2009, 127:163-170.
137. Kolter T., Winau F., Schaible U.E., Leippe M., Sandhoff K. Lipid-binding proteins in membrane digestion, antigen presentation, and antimicrobial defense. J. Biol. Chem. 2005, 280:41125-41128.
138. Wilkening G., Linke T., Sandhoff K. Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. J. Biol. Chem. 1998, 273:30271-30278.
139. Liepinsh E., Andersson M., Ruysschaert J.M., Otting G. Saposin fold revealed by the NMR structure of NK-lysin. Nat. Struct. Biol. 1997, 4:793-795.
140. Hecht O., Van Nuland N.A., Schleinkofer K., Dingley A.J., Bruhn H., Leippe M., Grotzinger J. Solution structure of the pore forming protein of entamoeba histolytic. J. Biol. Chem. 2004, 279:17834-17841.
141. de Alba E., Weiler S., Tjandra N. Solution structure of human saposin C: pH-dependent interaction with phospholipid vesicles. Biochemistry 2003, 42:14729-14740.
142. Ahn V.E., Leyko P., Alattia J.R., Chen L., Prive G.G. Crystal structures of saposins A and C. Protein Sci. 2006, 15:1849-1857.
143. Ahn V.E., Faull K.F., Whitelegge J.P., Fluharty A.L., Prive G.G. Crystal structure of saposin B reveals a dimeric shell for lipid binding. Proc. Natl. Acad. Sci. USA 2003, 100:38-43.
144. Popovic K., Prive G.G. Structures of the human ceramide activator protein saposin D. Acta Crystallogr. D. Biol. Crystallogr. 2008, 64:589-594.
145. Gutsmann T., Riekens B., Bruhn H., Wiese A., Seydel U., Leippe M. Interaction of amoebapores and NK-Lysin with symmetric phospholipid and asymmetric lipopolysaccharide/phospholipid bilayers. Biochemistry 2003, 42:9804-9812.
146. Fürst W., Machleidt W., Sandhoff K. The precursor of sulfatide activator protein is processed to three different proteins. Biol. Chem. Hoppe Seyler 1988, 369:317-328.
147. O'Brien J.S., Kretz K.A., Dewji N., Wenger D.A., Esch F., Fluharty A.L. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 1988, 241:1098-1101.
148. Nakano T., Sandhoff K., Stumper J., Christomanou H., Suzuki K. Structure of full-length cDNA coding for sulfatide activator, a Co-β-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J. Biochem. 1989, 105:152-154.
149. Leonova T., Qi X., Bencosme A., Ponce E., Sun Y., Grabowski G.A. Proteolytic processing patterns of prosaposin in insect and mammalian cells. J. Biol. Chem. 1996, 271:17312-17320.
150. Lefrancois S., Zeng J., Hassan A.J., Canuel M., Morales C.R. The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J. 2003, 22:6430-6437.
151. Hiesberger T., Hüttler S., Rohlmann A., Schneider W., Sandhoff K., Herz J. Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP). EMBO J. 1998, 17:4617-4625.
152. Fujita N., Suzuki K., Vanier M.T., Popko B., Maeda N., Klein A., Henseler M., Sandhoff K., Nakayasu H. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 1996, 5:711-725.
153. Burkhardt J.K., Hüttler S., Klein A., Möbius W., Habermann A., Griffiths G., Sandhoff K. Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. Eur. J.Cell Biol. 1997, 73:10-18.
154. Matsuda J., Vanier M.T., Saito Y., Tohyama J., Suzuki K. A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum. Mol. Genet. 2001, 10:1191-1199.
155. Mehl E., Jatzkewitz H. A cerebrosidesulfatase from swine kidney. Hoppe Seylers Z. Physiol. Chem. 1964, 339:260-276.
156. Li S.C., Sonnino S., Tettamanti G., Li Y.T. Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J. Biol. Chem. 1988, 263:6588-6591.
157. Fischer G., Jatzkewitz H. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim. Biophys. Acta 1977, 481:561-572.
158. Vogel A., Schwarzmann G., Sandhoff K. Glycosphingolipid specificity of the human sulfatide activator protein. Eur. J. Biochem. 1991, 200:591-597.
159. Kretz K.A., Carson G.S., Morimoto S., Kishimoto Y., Fluharty A.L., O'Brien J.S. Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc. Natl. Acad. Sci. USA 1990, 87:2541-2544.
160. Sun Y., Witte D.P., Ran H., Zamzow M., Barnes S., Cheng H., Han X., Williams M.T., Skelton M.R., Vorhees C.V., Grabowski G.A. Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice. Hum. Mol. Genet. 2008, 17:2345-2356.
161. John M., Wendeler M., Heller M., Sandhoff K., Kessler H. Characterization of human saposins by NMR spectroscopy. Biochemistry 2006, 45:5206-5216.
162. Rossmann M., Schultz-Heienbrok R., Behlke J., Remmel N., Alings C., Sandhoff K., Saenger W., Maier T. Crystal structures of human saposins C and D: implications for lipid recognition and membrane digestion. Structure 2008, 16:809-817.
163. Schultz-Heienbrok R., Remmel N., Klingenstein R., Rossocha M., Sandhoff K., Saenger W., Maier T. Crystallization and preliminary characterization of three different crystal forms of human saposin C heterologously expressed in Pichia pastoris. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun 2006, 62:117-120.
164. Alattia J.R., Shaw J.E., Yip C.M., Privé G.G. Direct visualization of saposin remodelling of lipid bilayers. J. Mol. Biol. 2006, 362:943-953.
165. Jin G.Z., Kubo H., Kashiba M., Horinouchi R., Hasegawa M., Suzuki M., Sagawa T., Oizumi M., Fujisawa A., Tsukamoto H., Yoshimura S., Yamamoto Y. Saposin B is a human coenzyme Q10-binding/transfer protein. J. Clin. Biochem. Nutr. 2008, 42:167-174.
166. Jin G.Z., Horinouchi R., Sagawa T., Orimo N., Kubo H., Yoshimura S., Fujisawa A., Kashiba M., Yamamoto Y. Coenzyme Q10-binding/transfer protein saposin B also binds gamma-tocopherol. J. Clin. Biochem. Nutr. 2008, 43:95-100.
167. Ho M.W., O'Brien J.S. Gaucher's disease: deficiency of 'acid' β-glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl. Acad. Sci. USA 1971, 68:2810-2813.
168. Sun Y., Qi X., Grabowski G.A. Saposin C is required for normal resistance of acid β-glucosidase to proteolytic degradation. J. Biol. Chem. 2003, 278:31918-31923.
169. Fabbro D., Grabowski G.A. Human acid β-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites. J. Biol. Chem. 1991, 266:15021-15027.
170. Vaccaro A.M., Ciaffoni F., Tatti M., Salvioli R., Barca A., Tognozzi D., Scerch C. PH-dependent conformational properties of saposins and their interactions with phospholipid membranes. J. Biol. Chem. 1995, 270:30576-30580.
171. Christomanou H., Aignesberger A., Linke R.P. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol. Chem. Hoppe-Seyler 1986, 367:879-890.
172. Schnabel D., Schröder M., Sandhoff K. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett. 1991, 284:57-59.
173. Alattia J.R., Shaw J.E., Yip C.M., Privé G.G. Molecular imaging of membrane interfaces reveals mode of β-glucosidase activation by saposin C. Proc. Natl. Acad. Sci. USA 2007, 104:17394-17399.
174. Klein A., Henseler M., Klein C., Suzuki K., Harzer K., Sandhoff K. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem. Biophys. Res. Commun. 1994, 200:1440-1448.
175. Ciaffoni F., Salvioli R., Tatti M., Arancia G., Crateri P., Vaccaro A.M. Saposin D solubilizes anionic phospholipid-containing membranes. J. Biol. Chem. 2001, 276:31583-31589.
176. Matsuda J., Kido M., Tadano-Aritomi K., Ishizuka I., Tominaga K., Toida K., Takeda E., Suzuki K., Kuroda Y. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse. Hum. Mol. Genet. 2004, 13:2709-2723.
177. Sun Y., Witte D.P., Zamzow M., Ran H., Quinn B., Matsuda J., Grabowski G.A. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and α-hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum. Mol. Genet. 2007, 16:957-971.
178. Conzelmann E., Sandhoff K. Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe Seylers Z. Physiol. Chem. 1979, 360:1837-1849.
179. Conzelmann E., Burg J., Stephan G., Sandhoff K. Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2. Eur. J. Biochem. 1982, 123:455-464.
180. Wright C.S., Li S.C., Rastinejad F. Crystal structure of human GM2-activator protein with a novel β-cup topology. J. Mol. Biol. 2000, 304:411-422.
181. Wright C.S., Zhao Q., Rastinejad F. Structural analysis of lipid complexes of GM2-activator protein. J. Mol. Biol. 2003, 331:951-964.
182. Wendeler M., Hoernschemeyer J., Hoffmann D., Kolter T., Schwarzmann G., Sandhoff K. Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation. Eur. J. Biochem. 2004, 271:614-627.
183. Ran Y., Fanucci G.E. Ligand extraction properties of the GM2 activator protein and its interactions with lipid vesicles. Biophys. J. 2009, 97:257-266.
184. Giehl A., Lemm T., Bartelsen O., Sandhoff K., Blume A. Interaction of the GM2-activator protein with phospholipid-ganglioside bilayer membranes and with monolayers at the air-water interface. Eur. J. Biochem. 1999, 261:650-658.
185. Wendeler M., Werth N., Maier T., Schwarzmann G., Kolter T., Schoeniger M., Hoffmann D., Lemm T., Saenger W., Sandhoff K. The enzyme-binding region of human GM2-activator protein. FEBS J. 2006, 273:982-991.
186. Schwarzmann G., Wendeler M., Sandhoff K. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system. Glycobiology 2005, 15:1302-1311.
187. Rigat B., Reynaud D., Smiljanic-Georgijev N., Mahuran D. The GM2 activator protein, a novel inhibitor of platelet-activating factor. Biochem. Biophys. Res. Commun. 1999, 258:256-259.
188. Wright C.S., Mi L.Z., Rastinejad F.J. Evidence for lipid packaging in the crystal structure of the GM2-activator complex with platelet activating factor. Mol. Biol. 2004, 342:585-592.
189. Wright C.S., Mi L.Z., Lee S., Rastinejad F. Crystal structure analysis of phosphatidylcholine-GM2-activator product complexes: evidence for hydrolase activity. Biochemistry 2005, 44:13510-13521.
190. Starostina E., Xu A., Lin H., Pikielny C.W. A Drosophila protein family implicated in pheromone perception is related to Tay-Sachs GM2-activator protein. J. Biol. Chem. 2009, 284:585-594.
191. Bruce A.F., Gares M.P., Selkirk M.E., Gounaris K. Functional characterisation of a nematode secreted GM2-activator protein. Mol. Biochem. Parasitol. 2006, 147:224-229.
192. Storch J., Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim. Biophys. Acta 2009, 1791:671-678.
193. Liu J.-P. New functions of cholesterol binding proteins. Mol. Cell. Endocrinol. 2009, 303:1-6.
194. Patterson M.C. A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurology 2003, 9:301-310.
195. Patterson M.C., Vanier M.T., Suzuki K., Morris J.A., Carstea E., et al. Niemann-Pick disease type C: a lipid trafficking disorder. 8th edn. 2001, vol. III:3611-3633. McGraw-Hill, New York, Chapter 145. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
196. Zervas M., Dobrenis K., Walkley S.U. Neurons in Niemann-Pick disease Type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 2001, 60:49-64.
197. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997, 277:228-231.
198. Naureckiene S., Sleat D.E., Lackland H., Fensom A., Vanier M.T., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290:2298-2301.
199. Millat G., Marcais C., Rafi M.A., Yamamoto T., Morris J.A., et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. Am. J. Hum. Genet. 1999, 65:1321-1329.
200. Millat G., Chikh K., Naureckiene S., Sleat D.E., Fensom A.H., et al. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. J. Hum. Genet. 2001, 69:1013-1021.
201. Okamura N., Kiuchi S., Tamba M., Kashima T., Hiramoto S., et al. A porcine homolog of the major secretory protein of human epididymis, HE1, specifically binds cholesterol. Biochim. Biophys. Acta 1999, 1438:377-387.
202. Liou H.L., Dixit S.S., Xu S., Tint G.S., Stock A.M., Lobel P. NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols. J. Biol. Chem. 2006, 281:36710-36723.
203. Cheruku S.R., Xu Z., Dutia R., Lobel P., Storch J. Mechanism of cholesterol transfer from the Niemann-Pick type C2 protein to model membranes supports a role in lysosomal cholesterol transport. J. Biol. Chem. 2006, 281:31594-31604.
204. Xu Z., Farver W., Kodukula S., Storch J. Regulation of sterol transport between membranes and NPC2. Biochemistry 2008, 47:11134-11143.
205. Babalola J.O., Wendeler M., Breiden B., Arenz C., Schwarzmann G., Locatelli-Hoops S., Sandhoff K. Development of an assay for the intermembrane transfer of cholesterol by Niemann-Pick C2 protein. Biol. Chem. 2007, 388:617-626.
206. Xu S., Benoff B., Liou H.-L., Lobel P., Stock A.M. Structural basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann-Pick type C2 disease. J. Biol. Chem. 2007, 282:23525-23531.
207. Kwon H., Abi-Mosleh L., Wang M.L., Deisenhofer J., Goldstein J.L., Brown M.S., Infante R.E. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009, 137:1213-1224.
208. Yanagimoto C., Harada M., Kumemura H., Koga H., Kawaguchi T., Terada K., Hanada S., Taniguchi E., Koizumi Y., Koyota S., Ninomiya H., Ueno T., Sugiyama T., Sata M. Niemann-Pick C1 protein transports copper to the secretory compartment from late endosomes where ATP7B resides. Exp. Cell Res. 2009, 315:119-126.
209. Liu B., Turley S.D., Burns D.K., Miller A.M., Repa J.J., Dietschy J.M. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1/mouse. Proc. Natl. Acad. Sci. USA 2009, 106:2377-2382.
210. Schrantz N., Sagiv Y., Liu Y., Savage P.B., Bendelac A., Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J. Exp. Med. 2007, 204:841-852.
211. Li Y., Thapa P., Hawke D., Kondo Y., Furukawa K., Furukawa K., Hsu F.F., Adlercreutz D., Weadge J., Palcic M.M., Wang P.G., Levery S.B., Zhou D. Immunologic glycosphingolipidomics and NKT cell development in mouse thymus. J. Proteome Res 2009, 8:2740-2751.
212. Crotzer V.L., Blum J.S. Cytosol to lysosome transport of intracellular antigens during immune surveillance. Traffic 2008, 9:10-16.
213. Münz C. Enhancing immunity through autophagy. Annu. Rev. Immunol. 2009, 27:423-449.
214. Angénieux C., Fraisier V., Maître B., Racine V., van der Wel N., Fricker D., Proamer F., Sachse M., Cazenave J.-P., Peters P., Goud B., Hanau D., Sibarita J.-B., Salamero J., de la Salle H. The Cellular pathway of CD1e in immature and maturing dendritic cells. Traffic 2005, 6:286-302.
215. de la Salle H., Mariotti S., Angenieux C., Gilleron M., Garcia-Alles L.F., Malm D., Berg T., Paoletti S., Maître B., Mourey L., Salamero J., Cazenave J.P., Hanau D., Mori L., Puzo G., De Libero G. Assistance of microbial glycolipid antigen processing by CD1e. Science 2005, 310:1321-1324.
216. De Libero G., Mori L. Mechanisms of lipid-antigen generation and presentation to T cells. Trends Immunol. 2006, 27:485-492.